Target Pool Sample Clauses

The Target Pool clause defines a specific group or set of resources, assets, or individuals that are designated for a particular purpose within an agreement. In practice, this clause outlines the criteria or characteristics that determine which items or persons are included in the pool, such as a list of eligible employees for a bonus program or a set of assets subject to a transaction. By clearly identifying the scope of what is covered, the Target Pool clause ensures clarity and prevents disputes over eligibility or inclusion, thereby streamlining administration and risk allocation.
Target Pool. OncoGenex will have a pool (the “Target Pool”) containing up to 2 slots for which OncoGenex can designate certain gene targets for collaborative research, development and commercialization under this Agreement (each such slot, a “Target Slot” and any gene target occupying such a slot, a “Collaboration Gene Target”). OncoGenex must designate at least one Collaboration Gene Target within the first 6 months following the Effective Date and the second Collaboration Gene Target within the first 24 months following the Effective Date. If OncoGenex fails to designate a Collaboration Gene Target by the applicable deadline above, it will lose its right to designate such Collaboration Gene Target.
View SourceView Similar (2)
Target Pool. (A) Reserved Target Slots. Initially, Isis will have a pool (the "Isis Target Pool") containing up to [**] slots for which Isis can designate certain Gene Targets solely for Antisense Drug Discovery Programs (each such slot, a "Target Slot" and any Gene Target occupying such a slot, a "Reserved Target"); provided, however, that on January 1 of each year starting with January 1, [**], Isis will gain the right to purchase one additional Target Slot by paying Alnylam [**] per each additional Target Slot, which additional Target Slot shall be a Co-Exclusive Target Slot except as otherwise provided in Section 6.4(f). These rights are cumulative and, subject to Section 17.2(c) do not expire during the License Term. Furthermore, in the event that Isis pays the $[**] license option fee for a Reserved Target pursuant to section 8.1, such Reserved Target will be considered to have graduated from the Isis Target Pool, and, subject to Section 6.4(e), Isis will be permitted to designate a new Reserved Target to fill the open Target Slot in the Isis Target Pool. (B) Initial Designations; Conversion of Target Slots. Initially, subject to Section 6.4(e), Isis can designate up to [**] Reserved Targets as Isis Exclusive Targets (the "Isis Exclusive Targets", and each Target Slot occupied by an Isis Exclusive Target, an "Exclusive Target Slot") and up to [**] Reserved Targets as Isis Co-Exclusive Targets (the "Isis Co-Exclusive Targets", and each Target Slot occupied by an Isis Co-Exclusive Target, a "Co-Exclusive Target Slot"). On January 1 of each year starting with January 1, [**], one of the [**] initial Co-Exclusive Target Slots will convert into an Exclusive Target Slot such that the initial [**] Target Slots will all be Exclusive Target Slots by January 1, [**]. Subject to section 6.4(f), the Isis Co-Exclusive Target in a Co-Exclusive Target Slot that converts to an Exclusive Target Slot will become an Isis Exclusive Target. (C) Removing/Adding/Redesignating Targets. After the Effective Date and no more than [**] period (a "Target Reallocation Period"), Isis may do any of the following: (i) Remove a Gene Target from the Isis Target Pool (which, following such removal will create an open Target Slot); (ii) Add a new Gene Target to any open Target Slot (subject to the procedures and provisions of Section 6.4(e); or (iii) Redesignate an Isis Co-Exclusive Target as an Isis Exclusive Target, provided that (A) an open Exclusive Target Slot is available, which may be made av...
View SourceView Similar (2)
Target Pool. As of the Effective Date, Regulus and AstraZeneca have identified in the R&D Plan three microRNAs as potential Oncology Targets (the “Target Pool” and each such microRNA properly included in the Target Pool, a “Target Pool microRNA”). Regulus represents that as of the Effective Date they are not aware of any Target Encumbrances other than the Regulus Existing Agreements for the Target Pool as of the Effective Date. During the first 12 months of the Research Term (or such longer time period during the Research Term as may be set forth in the R&D Plan), the JSC may substitute a different microRNA for an existing Target Pool microRNA; provided, that such substitute microRNA (i) is not the subject of an exclusive license or option for an exclusive license granted by Regulus to a Third Party or any other obligations of Regulus or its Affiliates that would prohibit Regulus from collaborating with AstraZeneca under this Agreement or from granting a license under Section 2.1 with respect to such microRNA, (ii) is not a Regulus Independent Program, and (iii) is primarily associated with the Oncology Field and (iv) Regulus will provide information on any Target Encumbrances applicable to such substitute microRNA, subject to Regulus’ confidentiality obligations in its Third Party Agreements. If the JSC substitutes a new microRNA for a prior Target Pool microRNA, then such new microRNA shall be a Target Pool microRNA, and such prior Target Pool microRNA shall not be a Target Pool microRNA. For clarity, in no event shall there be more than three microRNAs in the Target Pool at any time. For the avoidance of doubt any substitutions described in Section 3.4.2(a) are independent of the rights of substitution and substitution target as described in Section 3.4.
View Source
Target Pool. As of the Effective Date, ▇▇▇▇▇▇▇ and AstraZeneca have identified in the R&D Plan three microRNAs as potential Oncology Targets (the “Target Pool” and each such microRNA properly included in the Target Pool, a “Target Pool microRNA”). Regulus represents that as of the Effective Date they are not aware of any Target Encumbrances other than the Regulus Existing Agreements for the Target Pool as of the Effective Date. During the first 12 months of the Research Term (or such longer time period during the Research Term as may be set forth in the R&D Plan), the JSC may substitute a different microRNA for an existing Target Pool microRNA; provided, that such substitute microRNA (i) is not the subject of an exclusive license or option for an exclusive license granted by ▇▇▇▇▇▇▇ to a Third Party or any other obligations of Regulus or its Affiliates that would prohibit Regulus from collaborating with AstraZeneca under this Agreement or from granting a license under Section 2.1 with respect to such microRNA, (ii) is not a Regulus Independent Program, and (iii) is primarily associated with the Oncology Field and
View Source
Target Pool. The Target Pool, as defined herein (“Target Pool”), identifies up to [***] gene targets including the gene targets selected for collaborative Research, Development and Commercialization under the Research Program (each such gene target is a “Selected Gene Target”). The number of Selected Gene Targets is initially limited to [***], but this limit may be increased as contemplated by clause (iii) of Section 3.6.2 below or upon mutual written agreement of the Parties. The gene targets that are part of the Target Pool (including which of such gene targets are the Selected Gene Targets and whether such gene target is in “Stage 1” or “Stage 2” under the R&D Plan) will be listed on APPENDIX 12, which may be updated from time to time by the Parties in accordance with this Agreement. OMI will have [***] following the Effective Date to designate the initial gene targets it wants to place in the Target Pool. In addition, OMI, at a minimum, must select the first [***] Selected Gene Targets on or before the Effective Date.
View Source
Target Pool 
View Source

Related to Target Pool

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Target 3.1 The target is set out in Schedule 6 to this Agreement, as varied from time to time. 3.2 Whether the target has been met must be determined in accordance with Rule 6. 3.3 The Secretary of State may carry out a review of the sector commitment during 2016 for the target periods 1st January 2017 to 31st December 2018 and 1st January 2019 to 31st December 2020. The target may be varied to take account of the review in accordance with the procedure set out in Rule 12. 3.4 The target may also be varied in accordance with Rules 6, 9, 10 and 11.

  • Target Net Assets The Company agrees that the Target Business that it acquires must have a fair market value equal to at least 80% of the balance in the Trust Account at the time of signing the definitive agreement for the Business Combination with such Target Business (excluding taxes payable and the Deferred Underwriting Commissions). The fair market value of such business must be determined by the Board of Directors of the Company based upon standards generally accepted by the financial community, such as actual and potential sales, earnings, cash flow and book value. If the Board of Directors of the Company is not able to independently determine that the target business meets such fair market value requirement, the Company will obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions with respect to the satisfaction of such criteria. The Company is not required to obtain an opinion as to the fair market value if the Company’s Board of Directors independently determines that the Target Business does have sufficient fair market value.

  • Performance Targets Threshold, target and maximum performance levels for each performance measure of the performance period are contained in Appendix B.

  • Targets Seller’s supplier diversity spending target for Work supporting the construction of the Project prior to the Commercial Operation Date is ____ percent (___%) as measured relative to Seller’s total expenditures on construction of the Project prior to the Commercial Operation Date, and;